

Bankole A Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6655031/publications.pdf>

Version: 2024-02-01

41
papers

5,419
citations

236925

25
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

2923
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109074.	3.2	1
2	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. <i>JAMA Psychiatry</i> , 2019, 76, 374.	11.0	77
3	Toward Rational, Evidence-Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 703-707.	2.4	5
4	<sc>FDA</sc> and <sc>EMA</sc> Need Homology on Alcohol Outcome Measures<i>”Semper: Simplicitas est purius modum</i>. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1383-1384.	2.4	1
5	Analyzing repeated measures semi-continuous data, with application to an alcohol dependence study. <i>Statistical Methods in Medical Research</i> , 2016, 25, 133-152.	1.5	42
6	Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. , 2015, 37, 15-28.		8
7	Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 335-346.	1.0	11
8	The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 116, 107-115.	2.9	9
9	Topiramate for the Treatment of Cocaine Addiction. <i>JAMA Psychiatry</i> , 2013, 70, 1338.	11.0	110
10	Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. <i>Addiction Biology</i> , 2013, 18, 405-416.	2.6	21
11	In silico Models of Alcohol Dependence and Treatment. <i>Frontiers in Psychiatry</i> , 2012, 3, 4.	2.6	6
12	How Should Addiction-Related Research at the National Institutes of Health be Reorganized?. <i>Frontiers in Psychiatry</i> , 2011, 2, 2.	2.6	2
13	Should the Reorganization of Addiction-Related Research Across All the National Institutes of Health Be Structural?-The Devil Is Truly in the Details. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 572-580.	2.4	7
14	Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking. <i>American Journal of Psychiatry</i> , 2011, 168, 265-275.	7.2	180
15	Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients. <i>Current Pharmaceutical Design</i> , 2010, 16, 2103-2112.	1.9	241
16	Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for Alcohol Clinical Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2010, 34, 2022-2034.	2.4	156
17	Medication Treatment of Different Types of Alcoholism. <i>American Journal of Psychiatry</i> , 2010, 167, 630-639.	7.2	135
18	Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. <i>Biochemical Pharmacology</i> , 2008, 75, 34-56.	4.4	246

#	ARTICLE	IF	CITATIONS
19	Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 209-216.	4.8	36
20	A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 1-14.	2.1	58
21	Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals With Topiramate Treatment<sub>title>US Multisite Randomized Controlled Trial</sub>. <i>Archives of Internal Medicine</i> , 2008, 168, 1188.	3.8	109
22	Topiramate for Treating Alcohol Dependence<sub>title>A Randomized Controlled Trial</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1641.	7.4	490
23	Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 455-461.	4.8	10
24	Naltrexone long-acting formulation in the treatment of alcohol dependence. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 741-9.	2.0	26
25	Topiramate reduces the harm of excessive drinking: implications for public health and primary care. <i>Addiction</i> , 2006, 101, 1561-1568.	3.3	44
26	Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2003.	7.4	1,680
27	Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 203-213.	2.1	17
28	Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. <i>Psychopharmacology</i> , 2005, 178, 296-302.	3.1	30
29	Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 15-20.	4.8	16
30	Oral Topiramate Reduces the Consequences of Drinking and Improves the Quality of Life of Alcohol-Dependent Individuals. <i>Archives of General Psychiatry</i> , 2004, 61, 905.	12.3	154
31	Uses of topiramate in the treatment of alcohol dependence. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 751-758.	2.8	21
32	Progress in the Development of Topiramate for Treating Alcohol Dependence: From a Hypothesis to a Proof-of-Concept Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2004, 28, 1137-1144.	2.4	72
33	An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1943-1955.	1.8	36
34	Topiramate-induced neuromodulation of corticoâ€“mesolimbic dopamine function: A new vista for the treatment of comorbid alcohol and nicotine dependence?. <i>Addictive Behaviors</i> , 2004, 29, 1465-1479.	3.0	59
35	Effects of Isradipine on Cocaine-Induced Subjective Mood. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 180-191.	1.4	18
36	Ondansetron Reduces Mood Disturbance Among Biologically Predisposed, Alcohol-Dependent Individuals. <i>Alcoholism: Clinical and Experimental Research</i> , 2003, 27, 1773-1779.	2.4	54

#	ARTICLE	IF	CITATIONS
37	Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. <i>Lancet</i> , The, 2003, 361, 1677-1685.	13.7	718
38	Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprosate, Both Alone and Combined, in Alcohol-Dependent Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 281-293.	1.4	61
39	The role of serotonergic agents as treatments for alcoholism. <i>Drugs of Today</i> , 2003, 39, 665.	2.4	12
40	Combining Ondansetron and Naltrexone Treats Biological Alcoholics: Corroboration of Self-Reported Drinking by Serum Carbohydrate Deficient Transferrin, A Biomarker. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 847-849.	2.4	26
41	Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 963.	7.4	385